Blood-Brain Barrier Technologies and Global Markets

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Blood-Brain Barrier Technologies and Global Markets
Published on March 2011

Report Summary

REPORT HIGHLIGHTS

*
The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387
million by 2015, a compound annual growth rate (CAGR) of 99.3%.
*
The most common means of BBB passage or type of technology will be receptor-mediated transport (RMT), meaning crossing the
BBB via certain receptors that include the insulin or transferrin receptors. This technology was valued at $12 million in 2010 and is
expected to increase at a nearly 99% compound annual growth rate (CAGR) to reach $376 million in 2015.
*
The other technology to emerge as a vehicle for taking a drug across the BBB that otherwise could not cross it is carrier-mediated
transport. This sector was valued at $0.2 million in 2010 and is expected to increase at a 121% compound annual growth rate
(CAGR) to reach $10.5 million in 2015.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
BCC's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB)
technologies, including its growth potential over a 5-year period from 2010 to 2015. Our key objective was to present a
comprehensive analysis of the current BBB technology and drug development market and its future direction with the aim to first
define and classify that technology as it pertains to therapeutics in which the technology enables the therapeutic to directly cross
rather than bypass the BBB.

REASONS FOR DOING THIS STUDY

BBB technologies are going to open up a vast untapped potential in the growing central nervous system therapeutic market where
today growth is limited by the complexity of this layer in the brain that prevents the passage of many potentially useful
molecules/compounds.

This report offers a picture of this technology potential that is on the verge of rapid increase. Therapeutics make up the main area of
investment related to this technology; and, therefore, that is this report's focus. BCC has not yet examined the BBB, although the
central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.

SCOPE OF REPORT

The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development
in which a quality of the development is enabling the crossing of the BBB in cases in which passage was previously impossible often
due to size. BCC analyzes each technology, determines its current market status, examines its impact on future markets, and
presents forecasts of growth over the next 5 years. Technological issues, including the latest trends, are discussed.

Blood-Brain Barrier Technologies and Global Markets (From Slideshare) Page 1/9


INTENDED AUDIENCE

In the report, BBB technology is described in terms of what it is and its history in medicine, the types and technology categories, major
companies, impact on the pharmaceutical market, applications, current market values, growth potential, and significant trends. This
study will be of interest to the biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and
diagnostic test manufacturing companies as well as all those interested or actively working in drug and imaging agent research and
investors in all of the above.

METHODOLOGY

BCC presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of
BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are
based on actual aggregate sales for the years discussed. Information, in general, is compiled through a combination of primary and
secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES

BCC's analysis includes the review of more than 50 companies and information from financial and trade publications as well as the
U.S. Food and Drug Administration. Included were pharmaceutical and biotechnology companies as well as support companies to
them.

Table of Content

CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
SCOPE OF REPORT 1
INTENDED AUDIENCE 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 2
RELATED BCC REPORTS 2
BCC ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER TWO: EXECUTIVE SUMMARY 4
EXECUTIVE SUMMARY 4
EXECUTIVE SUMMARY (CONTINUED) 5
EXECUTIVE SUMMARY (CONTINUED) 6
EMERGING BBB TECHNOLOGY MARKET 7
EMERGING BBB TECHNOLOGY MARKET (CONTINUED) 8
KEY DRIVERS 9
KEY CHALLENGES 10
MAJOR TRENDS 11
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR



THERAPEUTICS, THROUGH 2015 ($ MILLIONS) 12
CHAPTER THREE: OVERVIEW 13
TODAY'S PHARMA MARKET 13
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL
DRUGS, BY REGION, 2009 AND 2015 (PERCENT OF GLOBAL
SALES) 14
FIGURE 2 EMERGING MARKETS' GROWTH IN PHARMACEUTICAL
SALES, 2015 (ESTIMATED $ BILLIONS) 15
TODAY'S PHARMA MARKET (CONTINUED) 16
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR
THERAPEUTICS, BY REGION, 2015* ($ MILLIONS) 17
BIOLOGICS 18
FIGURE 4 INVESTMENT IN BIOLOGICS AS A PERCENTAGE OF
TOTAL R&D, 2009 (PERCENT OF TOTAL R&D) 18
BIOLOGICS (CONTINUED) 19
GENERICS SIGNAL NEED FOR INNOVATION 20
NEUROFOCUSING IN THE PHARMA INDUSTRY 20
FIGURE 5 CNS REVENUE DISTRIBUTION BY DISEASE TARGET,
2009 ($ BILLIONS) 21
FIGURE 5 (CONTINUED) 22
THERAPEUTICS, 2015 AND 2017 (NUMBER OF UNITS) 22
THERAPEUTICS, BY INDICATION, 2015 AND 2017 (NUMBER OF
UNITS PER INDICATION) 23
NEUROFOCUSING IN THE PHARMA ' (CONTINUED) 25
TABLE 1 TOP PHARMA COMPANIES BY REVENUE, 2009 ($
BILLIONS) 26
EMERGING BBB TECHNOLOGY MARKET 26
BRIEF HISTORY OF BBB 27
BLOOD BRAIN BARRIER DEFINED 28
BBB COMPONENTS 29
FIGURE 8 PARTS OF THE BBB 30
BBB ILLUSTRATED 30
MAIN AREAS OF THE BRAIN 31
FIGURE 9 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO
BLOOD VESSELS 31
TREATING DISEASE AND THE BBB 32
MENINGITIS 33
MULTIPLE SCLEROSIS (MS) 33
ENCEPHALITIS 34
ALZHEIMER'S DISEASE (AD) 34
PARKINSON'S DISEASE (PD) 35
BBB TECHNOLOGY CLASSIFICATION 36
MOST COMMON BBB TECHNOLOGY 37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY



USED 38
TRANSPORT CONSIDERATIONS 39
BYPASSING THE BBB 39
BBB TECHNOLOGY DETAILED 40
CHEMICAL TRANSPORT SYSTEMS 40
BIOLOGICAL CARRIER OR TRANSPORT SYSTEMS 40
PHYSICAL FORCE (ENERGETIC) OPENING THROUGH
SOUND WAVES (TARGETED ULTRASOUND) 41
Physical Force (Energetic) Opening'(Continued) 42
FIGURE 10 METHODS OF CROSSING THE BBB 43
ENHANCING BIOLOGICAL TRANSPORT SYSTEM TECHNIQUES 44
NANOPARTICLES AND LIPOSOMES 44
NANOPARTICLES 44
TABLE 2 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB
TECHNOLOGY 45
Challenges with Nanoparticles 46
Liposomes 47
Liposomes (Continued) 48
PATENTS AND INTELLECTUAL PROTECTION 49
TABLE 3 KEY BBB TECHNOLOGY PATENTS 49
PATENTS AND INTELLECTUAL (CONTINUED) 50
ARMAGEN'S PATENT ESTATE 51
ArmaGen's Patent Estate (Continued) 52
LIFE AFTER PATENTING 53
TABLE 4 SAMPLE OF 2010 FINANCIAL DEALS IN CNS
THERAPEUTICS 54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 55
TABLE 5 SAMPLE OF 2010 FINANCIAL DEALS IN BBB
TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL
COMPANY (ESTIMATED, $ MILLIONS) 55
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY
TECHNOLOGY TYPE IN THE DEVELOPMENT PIPELINE, 2010*
(%) 56
FIGURE 12 COMPOSITION OF BBB TECHNOLOGY BY
TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC
DRUG) MARKET, 2015 (%) 57
BBB TECHNOLOGY MARKET:' (CONTINUED) 58
FIGURE 13 DRUGS IN DEVELOPMENT USING BBB-PASSAGE
TECHNOLOGY, 2010 AND 2015 (NUMBER OF UNITS) 59
TABLE 6 BBB TECHOLOGY COMPANIES AND RESPECTIVE
TECHNOLOGICAL METHODOLOGY 60
TABLE 7 BBB TECHOLOGY COMPANIES AND CORPORATE
PARTNERS/LICENSING DEAL WITH LEAD DISEASE TARGET 61
GENZYME INNOVATES IN-HOUSE 61
DRUG DEVELOPMENT IN THE CNS 62
MULTIPLE MODELS MUST BE USED 63
BBB IS ITS OWN SITE OF INVESTIGATION 63
BBB is its Own Site of Investigation (Continued) 64



UNDERSTANDING INTERACTIONS AND BRAIN AREAS AS
DISTINCT 65
TABLE 8 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING
BBB TECHNOLOGIES 66
TABLE 8 (CONTINUED) 67
WHAT VALUES ARE BEST' 67
TABLE 9 FREQUENT DRUG DEVELOPMENT CHALLENGES AND
THEIR CLINICAL EFFECTS 68
PROMISING RESEARCH 69
PROMISING RESEARCH (CONTINUED) 70
PROMISING CNS DRUGS IN THE PIPELINE FOR POTENTIAL
USE WITH BBB TECHNOLOGY 73
BRAIN CANCER 74
TABLE 10 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2015 74
ANXIETY 76
TABLE 11 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH
2015 76
DEMENTIA 77
TABLE 12 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE,
THROUGH 2015 77
PARKINSON'S DISEASE 79
TABLE 13 GLOBAL PIPELINE FOR PARKINSON'S DISEASE,
THROUGH 2015 79
DEPRESSION 79
TABLE 14 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2015 80
PERSONALITY/PSYCHIATRIC DISORDERS 81
TABLE 15 GLOBAL PIPELINE FOR OTHER PSYCHIATRIC
DISORDERS, THROUGH 2015 82
SPINAL CORD INJURY 83
TABLE 16 GLOBAL PIPELINE FOR SPINAL CORD INJURY,
THROUGH 2015 83
ADDICTION DISORDERS 83
TABLE 17 GLOBAL PIPELINE FOR ADDICTION DISORDERS,
THROUGH 2015 84
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) 84
TABLE 18 GLOBAL PIPELINE FOR ATTENTION DEFICIT
HYPERACTIVITY DISORDER, THROUGH 2015 85
SLEEP DISORDERS 85
TABLE 19 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH
2015 85



CHAPTER FOUR: COMPANY PROFILES 87
ABLYNX NV 87
ABLYNX NV (CONTINUED) 88
ADENIOS, INC 89
ALLON THERAPEUTICS, INC 89
ANGIOCHEM INC 90
ANGIOCHEM INC (CONTINUED) 91
ARMAGEN TECHNOLOGIES, INC 92
ARMAGEN TECHNOLOGIES, INC (CONTINUED) 93
BIOASIS TECHNOLOGIES INC 94
BRAINCELLS INC 95
BRISTOL-MYERS SQUIBB 96
CAPSULUTION PHARMA AG 96
CELLIAL TECHNOLOGIES 97
CYPRESS BIOSCIENCES, INC 97
CENERX BIOPHARMA, INC 98
CEPHALON INC 99
COGNITION PHARMACEUTICALS LLC 99
CYTOS BIOTECHNOLOGY AG 100
DIAMEDICA INC 100
DAINIPPON SUMITOMO PHARMA (DSP) CO, LTD 100
ENVIVO PHARMACEUTICALS, INC 101
ELI LILLY AND COMPANY 102
GENZYME 103
FABRE-KRAMER PHARMACEUTICALS, INC 104
GERON CORPORATION 104
GERON CORPORATION (CONTINUED) 105
INSIGHTEC, LTD 106
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 107
IN CEREBRO 107
JANSSEN PHARMACEUTICA NV 108
H LUNDBECK A/S 108
H LUNDBECK A/S (CONTINUED) 109
TABLE 20 LUNDBECK'S CNS PIPELINE 110
MEDGENESIS THERAPEUTIX, INC (BIOVAIL LAB) 110
MEDIMMUNE 111
MEDINVENT LLC 111
MITHRIDION, INC 112
NEUROGENETIC PHARMACEUTICALS, INC 113
NEUROVIVE PHARMACEUTICAL AB 113
NSGENE A/S 114
NEUREN PHARMACEUTICALS LTD 115
OPTINOSE 115
OTSUKA AMERICA PHARMACEUTICAL, INC 116
PROTHERAGEN, INC 116
PFIZER 117
TABLE 21 PFIZER'S CNS PIPELINE 118



PHARMACO-CELL COMPANY LTD 118
PHARMIDEX 119
RAPTOR PHARMACEUTICAL CORP 120
ROCHE 121
SHIRE PLC 122
SANERON CCEL THERAPEUTICS, INC 123
SOLVO BIOTECHNOLOGY 123
SPENCER PHARMACEUTICAL 124
SOVICELL GMBH 125
SYNAGEVA BIOPHARMA 126
TARGACEPT, INC 127
TETRAGENEX PHARMACEUTICALS, INC 128
TO-BBB TECHNOLOGIES BV 128
TRANSMOLECULAR INC 129
TTY BIOPHARM 130
UCB 131
VECT-HORUS 131
XENOPORT 132
XIGEN SA 133


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Blood-Brain Barrier Technologies and Global Markets

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 4 850.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Blood-Brain Barrier Technologies and Global Markets

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Blood-Brain Barrier Technologies and Global Markets